Skip to content

Apalutamide 13CD3

Apalutamide 13CD3

Product Description
CAT No.
ALN-A086D02
CAS No.
NA
Mol. F.
C2013CH12D3F4N5O2S
Mol. Wt.
481.5
Stock
Please Inquire
RFQ
Chemical Name : 4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluoro-N-(methyl-13C-d3)benzamide
Smiles : O=C(N1C2=CN=C(C#N)C(C(F)(F)F)=C2)C3(CCC3)N(C4=CC(F)=C(C(N[13C]([2H])([2H])[2H])=O)C=C4)C1=S
Inchi : InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)/i1D3

Structure-Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)

Michael E. Jung,*,u2020 Samedy Ouk,u2020 Dongwon Yoo,u2020 Charles L. Sawyers,u2021,u00a7 Charlie Chen,u2021 Chris Tran,u2021 and John WongvipatnJ. Med. Chem. 2010, 53, 2779u20132796

Review of Synthetic Routes and Crystalline Forms of the Antiandrogen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide

,† Samedy Ouk,† Dongwon Yoo,† Charles L. Sawyers,‡,§ Charlie Chen,‡ Chris Tran,‡ and John Wongvipat – J. Med. Chem. 2010, 53, 2779–2796

Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists

David L. Hughes – Org. Process Res. Dev. 2020, 24, 3, 347–362

Request For Quotation

Related Products